GLP-1 drugs linked to 28% lower liver failure risk in elderly
The reported reduction adds hepatic outcomes to the growing list of secondary endpoints attributed to incretin therapy in older patients.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 16 02:44 ETSource: Daily Beirut
The wire
- 01A report states GLP-1 receptor agonists were associated with a 28% reduction in liver failure risk among elderly patients.
- 02Hepatology and metabolic clinicians increasingly field questions about liver outcomes from patients already on semaglutide or tirzepatide.
- 03Study design, cohort size, drug mix and funding were not detailed, and an association in older adults does not establish causation.
From the source
Read at dailybeirut.comGLP-1 Drugs Cut Liver Failure Risk by 28% in Elderly
